Tirzepatide
12 NDCs across 1 manufacturer|0 Generic,12 Brand
Tirzepatide is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 13, 2022. In 2024, Medicare Part D spent $6.3 billion on Tirzepatide across 5.1 million claims for 895,000 beneficiaries.
Tirzepatide is available as 12 NDCs from 1 manufacturer (0 generic, 12 brand), with NADAC prices from $525.85 to $538.69 per ML — a 2% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
12
0G / 12B
Manufacturers
1
competing in market
Price Spread
$525.85 – $538.69
per ML
7d Activity
avg +0.0% WoW · of 12 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Eli Lilly and Company manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
GLP-1 Receptor Agonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing TIRZEPATIDE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
MOUNJARO 2.5 MG/0.5 ML PEN | $538.6884 per ML | +0.01% |
MOUNJARO 10 MG/0.5 ML PEN | $538.6836 per ML | +0.01% |
MOUNJARO 7.5 MG/0.5 ML PEN | $538.6804 per ML | +0.01% |
MOUNJARO 5 MG/0.5 ML PEN | $538.6338 per ML | +0.01% |
MOUNJARO 12.5 MG/0.5 ML PEN | $538.5252 per ML | +0.01% |
MOUNJARO 15 MG/0.5 ML PEN | $538.5176 per ML | +0.01% |
ZEPBOUND 2.5 MG/0.5 ML PEN | $526.2042 per ML | +0.02% |
ZEPBOUND 5 MG/0.5 ML PEN | $526.0828 per ML | +0.01% |
ZEPBOUND 10 MG/0.5 ML PEN | $526.0461 per ML | +0.05% |
ZEPBOUND 7.5 MG/0.5 ML PEN | $526.0041 per ML | +0.04% |
ZEPBOUND 15 MG/0.5 ML PEN | $525.9221 per ML | +0.04% |
ZEPBOUND 12.5 MG/0.5 ML PEN | $525.8487 per ML | +0.01% |
Frequently Asked Questions
What is Tirzepatide used to treat?
Tirzepatide is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Tirzepatide?
In 2024, Medicare Part D spent $6.3 billion on Tirzepatide across 5.1 million claims for 895,000 beneficiaries.
How many Tirzepatide products are on the market?
The Tirzepatide drug market contains 12 NDCs from 1 manufacturer — 0 generic and 12 brand products.
What is the price range for Tirzepatide?
NADAC reference prices for Tirzepatide range from $525.8487 to $538.6884 per ML — a 2% difference between cheapest and most expensive.
Which manufacturers make Tirzepatide?
1 manufacturer lists Tirzepatide in NADAC. Ranked by number of NDCs, the largest are Eli Lilly and Company (12).
How has the price of Tirzepatide changed recently?
Over the past 7 days, 24 Tirzepatide NDCs rose and 0 fell, with a market-wide average change of +0.0%.